Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 13/20 | 0.61 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.61 |
| ▸ | AKR1C1 | Q04828 | 3/20 | 0.61 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4472317 | 1.00 | AKR1C3 (0.61) | AKR1C3AKR1C2AKR1C1PTGS2 | |
| SCHEMBL3392061 | 0.85 | AKR1C3 (0.62) | AKR1C3AKR1C2AKR1C1PTGS2 | |
| SCHEMBL3392063 | 0.85 | AKR1C3 (0.62) | AKR1C3AKR1C2AKR1C1PTGS2 | |
| SCHEMBL2659478 | 0.78 | GCK (0.74) | — | |
| SCHEMBL2659815 | 0.77 | GCK (0.65) | AKR1C3AKR1C2AKR1C1PTGS2 | |
| SCHEMBL2659818 | 0.77 | GCK (0.65) | AKR1C3AKR1C2AKR1C1PTGS2 | |
| SCHEMBL3389220 | 0.75 | AKR1C3 (0.59) | AKR1C3AKR1C2AKR1C1PTGS2 | |
| SCHEMBL2665984 | 0.75 | AKR1C3 (0.59) | AKR1C3AKR1C2AKR1C1PTGS2 | |
| SCHEMBL28273657 | 0.71 | PTGS2 (1.00) | AKR1C3AKR1C2AKR1C1PTGS2 | |
| SCHEMBL28456088 | 0.71 | PTGS2 (1.00) | AKR1C3AKR1C2AKR1C1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2168962-A2 | PHENYLACETAMIDES AND THEIR USE AS GLUCOKINASE MODULATORS | Prosidion Limited (GB) | 2010-03-31 | — | — | EP | disclosed |
| US-7582632-B2 | Tri(cyclo) substituted amide compounds | PROSIDION LIMITED (GB) | 2009-09-01 | — | — | US | disclosed |
| US-7582632-B2 | Tri(cyclo) substituted amide compounds | PROSIDION LIMITED (GB) | 2009-09-01 | — | — | US | disclosed |
| US-7582632-B2 | Tri(cyclo) substituted amide compounds | PROSIDION LIMITED (GB) | 2009-09-01 | — | — | US | disclosed |
| US-20070281946-A1 | TRI(CYCLO) SUBSTITUTED AMIDE COMPOUNDS | OSI PHARMACEUTICALS, INC. | 2007-12-06 | — | — | US | disclosed |
| US-20070281946-A1 | TRI(CYCLO) SUBSTITUTED AMIDE COMPOUNDS | OSI PHARMACEUTICALS, INC. | 2007-12-06 | — | — | US | disclosed |
| US-20070281946-A1 | TRI(CYCLO) SUBSTITUTED AMIDE COMPOUNDS | OSI PHARMACEUTICALS, INC. | 2007-12-06 | — | — | US | disclosed |
| US-7214681-B2 | Tri(cyclo) substituted amide compounds | PROSIDION LIMITED (GB) | 2007-05-08 | — | — | US | disclosed |
| US-7214681-B2 | Tri(cyclo) substituted amide compounds | PROSIDION LIMITED (GB) | 2007-05-08 | — | — | US | disclosed |
| US-7214681-B2 | Tri(cyclo) substituted amide compounds | PROSIDION LIMITED (GB) | 2007-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070281946-A1 | TRI(CYCLO) SUBSTITUTED AMIDE COMPOUNDS | IAPP, GPR119, SLC5A1 | AKR1C3 921/4885AKR1C2 590/4885AKR1C1 782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.